Despite Pfizer/Seagen’s Splash, Deals Are Staying Small
First Half 2023 Deal-Making Infographic
Although late 2022 and early 2023 saw a few large transactions, a look at deal activity in the first half of the year shows bolt-on M&A remains in vogue for biopharma. Alliances are down from first half 2022.
